News

Rob Quinn To Join BenevolentAI As Chief Financial Officer in January 2021

BenevolentAI was founded with the belief that innovative thinking united with purposeful technology can lead to innovation that will fundamentally change patients’ lives for the better.  As we scale our bold and audacious mission, we require equally specialist expertise to guide our growth and financial direction.

To help us meet this need, we are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021.  He will take overall responsibility for the Finance Organisation, with a focus on investor relations, fundraising, revenue opportunities and realising our long term growth plans.

Rob brings with him a wealth of scientific and financial experience, having served at GSK as Area Finance Director for Africa & Developing Countries, and as CFO of Silence Therapeutics plc, where he led their listing on Nasdaq. He obtained a PhD in Biochemistry from the University of Manchester and qualified as a Chartered Accountant at Deloitte, where he spent time working in corporate finance advisory within the life sciences sector.

"I am excited to be joining BenevolentAI as Chief Financial Officer” Rob commented, “Benevolent is a business with huge potential and big ambitions to transform the lives of patients, and I look forward to playing my part". 

Under Rob’s financial guidance, we will confidently continue to move towards greater levels of innovation by investing in building richer and better technology that will help uncover vital new treatments. 


More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022